Fig. 2: Progression of individual sensor outcome measures in individuals with PD on placebo (black) and prasinezumab (blue). | npj Digital Medicine

Fig. 2: Progression of individual sensor outcome measures in individuals with PD on placebo (black) and prasinezumab (blue).

From: Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

Fig. 2

Progression of sensor features which surpassed the exploratory threshold for a group effect in PASADENA Part 1 is shown: (a) passively monitored gesture power during non-gait segments; (b) hand-turning, least affected side; (c) U-turn test; (d) speeded tapping, most affected and (e) least affected sides; (f) hand-turning, most affected side. Data from both the RCT PASADENA Part 1 (first 52 weeks; placebo group data plotted in black, pooled prasinezumab group data plotted in blue) and PASADENA Part 2 (second 52 weeks) in which all participants received prasinezumab (all data plotted in blue) are shown. Only data collected prior to the start of dopaminergic therapy are analyzed and plotted. Statistics are reported beneath each figure: estimates from the LMEs are coefficients of the fortnight-by-treatment arm interaction term (difference in slopes between the two arms), while estimates from MMRM are reported as contrasts between the pooled prasinezumab and placebo arms at the last study fortnight in the analysis.

Back to article page